Itoco

Dorzolamide, the active ingredient in Itoco, is a carbonic anhydrase inhibitor presented as a topical ophthalmic solution for ocular (topical) use. It lowers intra‑ocular pressure and is employed in the management of primary open‑angle glaucoma and ocular hypertension in adult patients, helping to prevent optic nerve damage.

GNH USA supplies Itoco as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing EU‑standard quality and reliable global distribution.

Dorzolamide is used in glaucoma therapy to reduce intra‑ocular pressure by decreasing aqueous humor production.

Primary open‑angle glaucoma: lowers intra‑ocular pressure to protect the optic nerve. Ocular hypertension: reduces eye pressure to prevent progression to glaucoma. Secondary open‑angle glaucoma: assists in controlling pressure when other causes are present.

Common Side Effects: - Transient ocular burning or stinging after instillation. - Blurred vision that resolves shortly after use. - Altered taste sensation when the solution drains into the throat. - Mild eye discomfort or redness. - Headache.

Serious or Rare Side Effects: - Severe allergic reaction including swelling of the eyelids or face. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Corneal edema or persistent corneal opacity. - Significant intra‑ocular inflammation. - Sudden loss of vision.

Before using Itoco, consider the following precautions.

Pregnancy: safety not established; use only if benefit outweighs risk. Breastfeeding: unknown safety; evaluate potential risks. Contact lens wearers: may cause discomfort; remove lenses before instillation. Concurrent ocular hypotensives: monitor intra‑ocular pressure closely. Sulfonamide allergy: avoid if patient has known hypersensitivity. Store at room temperature: keep in original container, protect from light and moisture.

Dorzolamide may interact with other medications; monitor as indicated.

Major Interactions (Avoid): - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive IOP‑lowering may cause hypotony. - Topical beta‑blockers: increased risk of excessive ocular hypotension. - Topical prostaglandin analogues: may reduce overall efficacy.

Moderate Interactions (Monitor Closely): - Oral sulfonamide antibiotics: potential cross‑reaction in sulfonamide‑sensitive patients. - Topical corticosteroids: may counteract IOP‑lowering effect and require monitoring.